Merck Gets a Shot of Confidence From Pivotal Test of SubQ Injectable Keytruda -...

Published on 19 Nov 2024 on MedCity News

Keytruda, a Merck cancer immunotherapy that has become the world’s top-selling medication, is...

Read the rest of the article

Start tracking your investments with Statfolio

For those looking for great candidates, here are two in the healthcare sector: Merck (NYSE: MRK) ...

Motley Fool · via Yahoo Finance 21 Nov 2024

A subcutaneous version of Merck’s Keytruda was as effective as the infused version in a late-stag...

Pharma Voice · via Yahoo Finance 21 Nov 2024

We recently published a list of Ken Griffin Stock Portfolio: 10 Stocks to Buy. In this article, w...

Insider Monkey · via Yahoo Finance 20 Nov 2024

Johnson & Johnson and Merck & Co. are cutting jobs in China, as they face growing competition fro...

Bloomberg 20 Nov 2024

On Tuesday, Merck & Co Inc (NYSE:MRK) revealed topline results from the pivotal Phase 3 MK-3475A-...

Benzinga · via Yahoo Finance 19 Nov 2024

Merck reported good news Tuesday on a more convenient version of its cancer drug Keytruda, a...

Barrons.com 19 Nov 2024

Keytruda, a Merck cancer immunotherapy that has become the world’s top-selling medication, is...

MedCity News 19 Nov 2024

We recently compiled a list of the Jim Cramer Talked About These 11 Stocks Recently. In this...

Insider Monkey · via Yahoo Finance 18 Nov 2024

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we a...

Insider Monkey · via Yahoo Finance 18 Nov 2024

Merck & Co.’s recent $1.3 billion deal to reel in Modifi Biosciences seemed to ignore pharma’s...

Pharma Voice · via Yahoo Finance 18 Nov 2024